These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Progestins in combined treatment of endometrial cancer]. Voznyĭ EK; Titova VA Sov Med; 1990; (9):102-7. PubMed ID: 2148437 [No Abstract] [Full Text] [Related]
9. Cytologic evaluation of exclusive medroxyprogesterone acetate treatment for vaginal recurrence of endometrial adenocarcinoma. Bonte J; Drochmans A; Ide P Acta Cytol; 1970 May; 14(5):353-6. PubMed ID: 5284269 [No Abstract] [Full Text] [Related]
10. [Effect of treatment with oral 6-methyl-17-hydroxyprogesterone acetate in endometrial adenocarcinoma. Histochemical and ultrastructural aspects]. Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S; Patton R Minerva Ginecol; 1981 Apr; 33(4):293-306. PubMed ID: 7243070 [No Abstract] [Full Text] [Related]
11. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. Schmid FA; Sirotnak FM; Otter GM; DeGraw JI Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of 5-fluorouracil plus melphalan in colorectal carcinoma. Presant CA; Ratkin G; Klahr C Cancer Treat Rep; 1978 Mar; 62(3):461-2. PubMed ID: 348317 [No Abstract] [Full Text] [Related]
13. The treatment of uterine adenocarcinoma with medroxyprogesterone acetate. Horger EO; Williamson HO; Hester LL J S C Med Assoc; 1966 Jun; 62(6):217-23. PubMed ID: 5227728 [No Abstract] [Full Text] [Related]
14. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Kline RC; Freedman RS; Jones LA; Atkinson EN Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831 [No Abstract] [Full Text] [Related]
15. [Effects of medroxyprogesterone (MAP) therapy on the DNA content in adenocarcinoma of the human endometrium]. Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S Minerva Ginecol; 1979; 31(7-8):597-603. PubMed ID: 481819 [No Abstract] [Full Text] [Related]
17. Vaginal cytologic evaluation as a practical link between hormone blood levels and tumor hormone dependency in exclusive medroxyprogesterone treatment of recurrent or metastatic endometrial adenocarcinoma. Bonte J; Decoster JM; Ide P Acta Cytol; 1977; 21(2):218-24. PubMed ID: 266331 [TBL] [Abstract][Full Text] [Related]
18. [Treatment with progestational agents in the advanced phase of carcinoma of the endometrium. Study of 137 patients treated at the 1st division of obstetrics and gynecology of the San Camillo De Lellis Hospital in Rome]. Rendina GM; Donadio C Minerva Ginecol; 1975 Dec; 27(12):1026-30. PubMed ID: 778677 [TBL] [Abstract][Full Text] [Related]
19. [Flow cytometric study on the action of progestogen in patients with adenocarcinoma and precancerous lesions of the endometrium]. Nishiya I; Izutsu T; Satoh K; Yoshizumi N; Kurokawa Y; Kagabu T Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jul; 37(7):1161-8. PubMed ID: 3161958 [TBL] [Abstract][Full Text] [Related]
20. [MAP in the treatment of adenocarcinoma of the endometrium]. Leone F; De Placido G; Frollo G Minerva Ginecol; 1979 Apr; 31(4):251-5. PubMed ID: 460664 [No Abstract] [Full Text] [Related] [Next] [New Search]